Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis

• Published in: Digestive and liver disease 2022-07, Vol.54 (7), p.871-877
• Main Authors: Moutinho-Ribeiro, P., Adem, B., Batista, I., Silva, M., Silva, S., Ruivo, C.F., Morais, R., Peixoto, A., Coelho, R., Costa-Moreira, P., Lopes, S., Vilas-Boas, F., Durães, C., Lopes, J., Barroca, H., Carneiro, F., Melo, S.A., Macedo, G.
• Format: Article
• Language: English
• Subjects: Biomarkers, Tumor; CA 19.9; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal - diagnosis; Carcinoma, Pancreatic Ductal - pathology; Chronic pancreatitis; Diagnosis, Differential; Endoscopic ultrasound; Glypican-1; Glypicans; Humans; Pancreatic ductal adenocarcinoma; Pancreatic Neoplasms; Pancreatic Neoplasms - diagnosis; Pancreatic Neoplasms - pathology; Pancreatitis, Chronic - diagnosis; Prospective Studies
• ISSN: 1590-8658; 1878-3562
• DOI: 10.1016/j.dld.2021.10.012

Pancreatic ductal adenocarcinoma (PDAC) diagnosis can be difficult in a chronic pancreatitis (CP) background, especially in its mass forming presentation. We aimed to assess the accuracy of glypican-1-positive circulating exosomes (GPC1+crExos) to distinguish PDAC from CP versus the state-of-the-art CA 19–9 biomarker. This was a unicentric prospective cohort. Endoscopic ultrasound with fine-needle aspiration or biopsy and blood tests (GPC1+crExos and serum CA 19–9) were performed. The cohort comprised 60 PDAC and 29 CP (7 of which mass forming - MF) patients. Median levels of GPC1+crExos were significantly higher in PDAC (99.7%) versus CP (28.4%; p